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Abstract
In order to metastasize, cancer cells need to acquire a motile phenotype. Previously, development of this phenotype was
thought to rely on the acquisition of selected, random mutations and thus would occur late in cancer progression. However,
recent studies show that cancer cells disseminate early, implying the existence of a different, faster route to the metastatic
motile phenotype. Using a spontaneous murine model of melanoma, we show that a subset of bone marrow-derived
immune cells (myeloid-derived suppressor cells or MDSC) preferentially infiltrates the primary tumor and actively promotes
cancer cell dissemination by inducing epithelial-mesenchymal transition (EMT). CXCL5 is the main chemokine attracting
MDSC to the primary tumor. In vitro assay using purified MDSC showed that TGF-b, EGF, and HGF signaling pathways are all
used by MDSC to induce EMT in cancer cells. These findings explain how cancer cells acquire a motile phenotype so early
and provide a mechanistic explanation for the long recognized link between inflammation and cancer progression.
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Introduction
Tumor metastasis is the primary cause of death by cancer [1].
Metastasis is a multistep process in which cancer cells derived from
the primary tumor migrate to regional or distant sites where they
re-initiate tumor development [2]. Until recently, the first step of
metastasis, (i.e. tumor cell dissemination) was thought to be a late
event in cancer progression [3]. This time-lag was presumably
needed to allow selected cancer cells to accumulate the additional
mutations required for motility. However, recent work, including
that of our laboratory, has challenged this paradigm. In fact,
cancer cells disseminate even before diagnosis of the primary
tumor [4–6], and so a different, faster mechanism must be driving
the development of the motile phenotype.
Tumors do not consist of a homogeneous population of cells;
rather they are a composite of cancer cells, mesenchymal and
endothelial cells, and immune cell populations. Among these
immune cells are the myeloid cells, which are generating
increasing interest as having a dynamic influence on tumor
growth. The link between cancer progression and infiltration with
myeloid cells was recognized by R. Virchow in the late 19
th
century [7–11]. Infiltration with myeloid cells is usually associated
with less favorable clinical outcomes. During the past decade
several distinct subsets of tumor-infiltrating myeloid cells have
been described [12], among which CD11b
+Gr1
+ MDSC have
drawn attention for having a role in cancer progression [13–16].
MDSC, which can be further divided into monocytic (Mo-)
MDSC and granulocytic (PMN-) MDSC, accumulate in most
malignant murine and human tumors [17–19]. These cells have
been shown to favor cancer progression by dampening anti-tumor
immune responses, promoting angiogenesis, and creating a pre-
metastatic environment [20–22].
RETAAD mice are transgenic for the activated RET oncogene,
which is specifically expressed in skin and eye melanocytes.
RETAAD mice spontaneously develop uveal melanomas that are
clinically detectable (exophthalmos) by 4 to 8 wk of age. In fact,
microscopic eye tumors can be detected as early as 10 d after birth
and cancer cells disseminate from the primary eye tumor
throughout the body by 3 wk of age [5,23]. Disseminated cancer
cells can be monitored in the eye draining lymph node and in the
lung by measuring ectopic expression of Dct (a specific marker of
melanocytes) or RET. The disseminated cancer cells remain
dormant for months before developing into cutaneous and then
visceral metastases. Previous work showed that most tumors
developing in a given mouse share a common clonal origin [5].
The stepwise evolution of melanoma in RETAAD mice mimics
the natural history of disease progression in cancer patients [24],
underlining the suitability of this model for dissecting the role of
immune cells in the process of metastasis.
PLoS Biology | www.plosbiology.org 1 September 2011 | Volume 9 | Issue 9 | e1001162Although melanocytes are not of epithelial origin, metastatic
melanoma cells undergo morphological changes resulting in
decreased intercellular adhesion and increased cellmotility,a process
that morphologically and mechanistically resembles epithelial-
mesenchymal transition (EMT) [25]. EMT is a trans-differentiation
process occurring during embryonic development and in carcinoma
progression [26]. In the present study we used RETAAD mice to
examine the presence and role of MDSC in melanoma metastasis.
Interestingly, we found that PMN-MDSC preferentially accumulate
in the primary tumor where they induce cancer cell EMT. PMN-
MDSC favor the rapid acquisition of a motile phenotype by cancer
cells resulting in multinodular growth of the primary tumor,
dissemination throughout the body and distant metastasis.
Results
Gradual Accumulation of PMN-MDSC in Tumor-Bearing
Mice
RETAAD mice develop uveal melanoma that metastasizes to the
skin and visceral organs. Tumor development at distant sites usually
takes more than 6 mo. As previously described in other tumor
models [18,19], we observed an increase in CD11b
+Gr1
+ cells in
both the spleen and blood during tumor progression (Figure S1A
and B, respectively). This increase begins as the primary tumor
starts to cause the eye to bulge (exophthalmos) and peaks once
distant metastases become palpable. As shown in Figure S1C,
purified CD11b
+Gr1
+ cells strongly inhibited antigen-specific T cell
proliferation in vitro and therefore represent bona fide MDSC.
PMN-MDSC Preferentially Accumulate in Primary Tumors
CD11b
+Gr1
+ MDSC are a heterogeneous population of myeloid
cells. To further characterize MDSC in the RETAAD model,
immune infiltrates of primary tumors and cutaneous metastases were
analyzed. CD45
+ immune cells represented on average 2.7% (95
CI=1.9%–3.5%)ofthetotalcellswithinatumor,ingoodagreement
with published data on spontaneous melanoma models [27] and
uveal melanoma patients [28]. Among immune cells infiltrating
cutaneous tumors (Figure 1A), lymphoid cells represented 28.6% (95
CI=20.1%–37.1%). The tumor-infiltrating myeloid cell population
comprised CD103
+CD11c
hi dendritic cells (3.6%, 95 CI=2.5%–
4.7%), CD11b
+CD11c
hi dendritic cells (5.8%, 95 CI=4.2%–7.4%),
B220
+CD11c
+ plasmacytoid dendritic cells (7.6%, 95 CI=3.3%–
11.0%), CD11b
+Gr1
2F4/80
+ macrophages (51.4%, 95 CI=42%–
61%) and CD11b
+Gr1
+ MDSC (6.7%, 95 CI=3.6%–9.8%).
MDSC could be further sub-divided into CD11b
+Gr1
hi F4/80
2
PMN-MDSC and CD11b
+Gr1
intF4/80
lo Mo-MDSC (Figure 1 and
Figure S1D). Interestingly, while most subsets of immune cells were
equally represented in primary tumors and cutaneous metastases
(Figure 1A), PMN-MDSC were 5 times more abundant in primary
tumors (Figure 1B and 1C, 24.5%61.5% of immune cells versus
3.9%60.2%; two-tailed t test p, 0.0001). In order to understand the
significance of this finding, we decided to examine the factors
controlling the preferential accumulation of PMN-MDSC in the
primary tumor and to investigate the role of these cells.
Primary Tumors Express PMN-MDSC Chemoattractants
To identify potential mediators of the preferential accumulation
of PMN-MDSC in primary tumors, the expression of 148
inflammatory genes including chemokines, inflammatory cyto-
kines, and their corresponding receptors was analyzed using low
density qRT-PCR arrays. When primary tumors and cutaneous
metastases from the same mice were compared, 21 genes were
identified as differentially expressed (fold change .2; p,0.05), of
which 20 were more highly expressed in the primary tumor than
in the corresponding skin tumor (Figure 1D and Table S1). The
most differentially expressed genes (fold change .4 and p,0.05)
were members of the IL-1 families and, interestingly, four
chemokines: CCL19, CXCL1, CXCL2, and CXCL5. For
example, the average expression of CXCL5 was 56-fold higher
in primary tumors than in cutaneous metastases (p=8.38610
25).
Transcriptome analysis of purified tumor-infiltrating immune cells
indicated that only PMN-MDSC express Il8rb (also known as
CXCR2), the receptor for CXCL1, CXCL2, and CXCL5 (Figure
S2). Furthermore, PMN-MDSC express CXCL1 and CXCL2
while tumors express CXCL5. We therefore tested the capacity of
these three chemokines to attract immune cells from tumor-
bearing RETAAD mice in vitro. As shown in Figure 1F–H,
CXCL1, CXCL2, and CXCL5 are indeed potent attractants for
PMN-MDSC, but not monocytes or lymphocytes. Moreover,
RETAAD tumor cells attracted PMN-MDSC in vitro and this
attraction was significantly reduced when PMN-MDSC were
treated with either SB265610 or SB225002, two specific inhibitors
of CXCR2 (Figure 1I). To establish the importance of CXCR2
ligands in the recruitment of PMN-MDSC to the primary tumors,
bone marrow cells from Rosa mT/mG reporter mice expressing
tdTomato (used as fluorescently tagged wild-type [wt] cells) and
CXCR2 knockout mice expressing GFP (IL8rb-KO crossed with
mice expressing EGFP under the lysozyme M promoter [Il8rb-
KO]) were mixed at a 1:1 ratio and adoptively transferred into
tumor-bearing RETAAD mice. After 18 h, primary tumors were
analyzed by flow cytometry for Gr1
hitdTomato
+ and Gr1
hiGFP
+
tumor-infiltrating PMN-MDSC. Wt PMN-MDSC were 7-fold
more abundant than PMN-MDSC from Il8rb-KO mice (Figure 1J).
This preferential migration was specific for the primary tumor as
equal proportions of wt and Il8rb-KO PMN-MDSC migrated to the
spleen. This shows that expression of CXCR2 is necessary for
PMN-MDSC migration into the primary tumor in vivo. Of the
three CXCR2 ligands, CXCL5 is the most highly expressed in
Author Summary
Cancer progression has been depicted as a linear process,
during which the incipient cancer cell sequentially
accumulates mutations that confer the ability to metasta-
size. However, recent studies show that cancer cells
disseminate early, before such mutations can accumulate,
implying the existence of a different, faster route to the
metastatic phenotype. Using a mouse model of melano-
ma, we show that the primary tumor attracts a subset of
immune cells that actively promote cancer cell motility,
dissemination, and metastasis. These tumor-infiltrating
immune cells do so by reactivating a cellular program
(mesenchymal transition) used by melanocytes during
their development to colonize the skin, and also believed
to be an essential step in cancer cell dissemination and
metastasis. Once the melanoma cells migrate out of the
primary tumor, they can lapse back to their original
phenotype and lose their migratory potential. This
transient phenotypic switch may accelerate carcinogenesis
and participate in the plasticity of cancer. It explains how
cancer cells might spread to other organs even before the
original tumor is detected. In addition to the evidence
gleaned from our mouse melanoma model, we show that
these immune cells induce typical features of epithelial-
mesechymal transition in both melanoma and bladder
human cell lines when examined in culture dishes. These
findings provide an underlying mechanism for the long-
recognized link between inflammation and cancer pro-
gression.
Tumor Cell Dissemination Is Driven by MDSC
PLoS Biology | www.plosbiology.org 2 September 2011 | Volume 9 | Issue 9 | e1001162Figure 1. CXCR2 ligands attract PMN-MDSC to the primary tumor. (A) Quantification of the subsets of immune cells infiltrating primary
tumors and cutaneous metastases. Data were obtained by flow cytometry from 20 cutaneous and 13 eye tumors. Numbers show the frequencies of
each subset among CD45
+ cells. Gating strategy for immune cell subsets is illustrated in Figure S1D. (B) Preferential accumulation of PMN-MDSC
(Gr1
hi F4/80
2) in primary tumors. Composition of the primary tumor and a cutaneous cheek tumor from the same mouse. Cells are gated on
CD45
+CD11c
2CD11b
+DAPI
2 tumor cells. (C) Frequency of PMN-MDSC in primary (n=13) and cutaneous (n=20) tumors. Bars represent mean 6 SEM.
***p value ,0.0001, two-tailed unpaired Student’s t test. (D) Repertoire of chemokines and cytokines differentially expressed in primary tumors and
metastases. Fold changes represent the log2 ratio of gene expression measured by qRT-PCR in primary tumors (n=11) and in the metastatic tumors
(n=11). p values were calculated by two-tailed paired Student’s t test. (E) Relative expression of CXCL1 (CX1), CXCL2 (CX2), and CXCL5 (CX5) in 11
primary tumors and 11 metastases measured by qRT-PCR. *p,0.05, ***p,0.001. (F–H) CXCL1 (F), CXCL2 (G), and CXCL5 (H) induce PMN-MDSC
chemotaxis in vitro, but have no effect on monocytes or T, B, and NK lymphocytes. x-axis represents the amount of chemokine added in ng/ml.
Percentage migration was calculated as (number of migrated cells) 6100/(total cells added per well). Data are from three independent experiments
carried out in duplicates. Bars represent mean 6 SEM *p,0.05, **p,0.01, ***p,0.001, two-tailed t test. (I) Inhibition of CXCR2 reduces PMN-MDSC
migration in vitro. PMN-MDSC were treated 1 h before and during the migration assay with CXCR2 inhibitors—Inh1 (SB265610) and Inh2 (SB225002).
Tumor Cell Dissemination Is Driven by MDSC
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mediator of the preferential recruitment of PMN-MDSC to the
primary tumor. In summary, primary tumors express unique
chemokines that specifically attract PMN-MDSC.
PMN-MDSC Favor the Growth of the Primary Tumor
To gain insight into the role of PMN-MDSC in primary tumors,
these cells were depleted using anti-Ly6G antibody NIMP-R14 [29].
The first injection of antibodies was given as soon as the primary
tumor became visible (5 wk of age), then repeated twice a week, until
the age of 20 wk when tumors were analyzed by flow cytometry and
immunohistochemistry (Figure S3A, scheme B). Antibody treatment
ablated PMN-MDSC (CD11b
+Gr1
hi) in the primary tumor and
spleen (determined at the time of sacrifice) and in the blood for the
duration of the experiment (Figure S3B). Importantly, the monocytic
subset of MDSC (Mo-MDSC, CD11b
+Gr1
loF4/80
lo)w a sn o t
affected by the depletion, whereas there was a slight increase in
macrophage number (CD11b
+Gr1
2F4/80
+) in the primary tumors
(Figure S3B). Interestingly, depletion of PMN-MDSC resulted in
reduced growth of the primary tumors (Figure 2A) but not cutaneous
tumors (Figure S4). At 20 wk of age, the mean diameter of primary
tumors was 4.7 times smaller in depleted mice compared to mice
treated with an isotype control antibody (mean diameter
1.960.5 mm versus 0.460.2 mm; two-tailed t test p=0.027).
Enhanced angiogenesis was unlikely to explain the effect of PMN-
MDSC on tumor growth since no significant difference in the density
of blood vessels or CD45
2CD31
+ endothelial cells existed between
PMN-MDSC-depleted and control tumors (Figure S5A and B). In
fact,there wasatrend towardsanincreased densityofCD45
2CD31
+
cells in the PMN-MDSC depleted mice. Taken together this shows
that PMN-MDSC favor the growth of the primary tumor.
PMN-MDSC Promote Cancer Cell Proliferation in the
Primary Tumor
To elucidate the mechanism by which PMN-MDSC favor
growth of the primary tumor, we focused on the early steps of
tumorigenesis. The depletion experiment was repeated starting at
1 wk of age, before any eye abnormality was detectable, and the
primary tumors were analyzed at 7 wk of age (Figure S3A, scheme
A). At this age macroscopic primary tumors are rarely detectable,
and when microscopic tumors were analyzed by immunohisto-
chemistry, no difference was observed in the size of the lesion
developing in treated and control mice (Figure S6). However
immunohistochemistry revealed that depletion of PMN-MDSC
results in a reduced frequency of proliferating cancer cells,
identified by double labeling with S100B- and Ki67-specific
antibodies (Figure 2C and D). As shown in Figure 2B, at 7 wk of
age, primary tumors exhibited a mitotic index of 3.5%60.6% that
was reduced to 1.7%60.1% (p=0.01) in PMN-MDSC depleted
mice. We calculated that such a 2-fold difference in the mitotic
indices would translate into a reduction in tumor diameter of just
under 2-fold at 7 wk and 4-fold at 20 wk, showing good agreement
with the observed 4.7-fold (Figure 2A and Text S1). Taken
together, MDSC depletion experiments showed that these cells
favor cancer cell proliferation (detected at 7 wk) leading to the
development of bigger primary tumors (at 20 wk).
PMN-MDSC Secrete Soluble Factors That Promote Cancer
Cell Proliferation In Vitro
To determine whether the effect of PMN-MDSC on cancer cell
proliferation was direct or required additional stromal components,
in vitro co-culture experiments were performed. Melan-ret cells, a
cell line derived from a RET tumor, were co-cultured for 48 h with
PMN-MDSC purified from tumor-bearing RETAAD mice. Cancer
cell proliferation was measured in vitro by [
3H]-thymidine
incorporation. Addition of PMN-MDSC resulted in increased
proliferation of the cancer cells in a dose-dependent manner
(Figure 3A). This effect was not due to proliferation of PMN-MDSC
since even irradiated PMN-MDSC induced cancer cell proliferation
(Figure 3B, p=0.035). Importantly this was specific to PMN-
MDSC, as co-culture with F4/80
+ cells purified from tumor-bearing
Percentage migration was calculated as (number of migrated cells) 6100/(total cells added per well). Data are from two independent experiments
carried out in duplicates. Bars represent mean 6 SEM *p,0.05, **p,0.01, two-tailed t test. (J) CXCR2 is required for PMN-MDSC accumulation into the
primary tumor. Equal numbers of bone marrow cells from Rosa mT/mG reporter mice expressing tdTomato (used as fluorescently tagged wild-type
[wt] cells) and Il8rb-KO mice expressing GFP were adoptively transferred into tumor-bearing RETAAD mice. The graph shows the contribution of each
genotype to donor-derived PMN-MDSC present in the primary tumor and spleen 18 h after transfer. Data are from four mice. Bars represent mean 6
SEM *p,0.05, **p,0.01, two-tailed t test.
doi:10.1371/journal.pbio.1001162.g001
Figure 2. PMN-MDSC favor tumor cell proliferation in the
primary tumor. (A) Five-week-old mice were depleted of PMN-MDSC
by bi-weekly injection of anti-Ly6G antibody (NIMP-R14) (depletion
scheme B). At 20 wk of age, mice were euthanized and the size of the
primary tumors was measured. Results are from a total of 22 tumors
derived from four depleted mice (Dp) and seven littermates injected
with a control antibody (Ct). (B–D) One-week-old mice were depleted of
PMN-MDSC by bi-weekly injection of anti-Ly6G antibody (depletion
scheme A). At 7 wk of age, mice were culled and eye tumors were
analyzed by two-color immunohistochemistry using S100B- (brown)
and Ki67- (blue) specific antibodies. (B) Comparison of the mitotic
indices measured in 172 nodules taken from eight depleted mice (Dp)
and 130 nodules from seven control littermates (Ct). Panels C and D
show representative examples of tumors from control and depleted
mice. Bars in panels A and B represent mean 6 SEM. *p value ,0.05,
two-tailed unpaired Student’s t test.
doi:10.1371/journal.pbio.1001162.g002
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Furthermore, it did not require direct contact between the PMN-
MDSC and the cancer cells as increased proliferation was also
observed when PMN-MDSC were separated from the cancer cells
bya porousmembrane(Figure 3C, p=0.025). Taken together, these
results show that PMN-MDSC secrete soluble mediators that
directly promote cancer cell proliferation.
PMN-MDSC Favor Multinodular Development of Primary
Tumors
In the RETAAD model, primary tumors of the eye display a
multinodular structure. Given that in this model, tumors from the
same mouse share a common clonal origin, this multinodular
structure was suggestive of early acquisition of a motile phenotype
[5,30–32]. We wondered whether PMN-MDSC played any role in
the migration of cancer cells to the tumor periphery. Primary
tumor morphology was analyzed by histology in 7-wk-old mice
that had been depleted of PMN-MDSC from 1 wk of age onward.
As shown in Figure 4, primary tumors from depleted mice (n=11)
had smaller numbers of nodules compared to control mice (n=11).
The average number of ocular nodules was 1164 in the depleted
mice and 1965 in the controls (two-tailed Wilcoxon p=0.04).
This result shows that PMN-MDSC play a role in development of
the multinodular structure of primary eye tumors by favoring the
migration of melanoma cells to the tumor periphery.
PMN-MDSC Induce Cancer Cell Dissemination to
Regional and Distant Sites
Given that PMN-MDSC favor the migration of melanoma cells
to the tumor periphery, we wondered whether they also promoted
cancer cell dissemination to more distant sites, such as the eye-
draining mandibular lymph nodes or the lungs. Daupachrome
tautomerase (Dct) is specifically expressed by melanocytic cells and
ectopic expression of Dct represents a sensitive surrogate marker of
cancer cell dissemination [5]. We therefore compared Dct
expression in the eye-draining mandibular lymph nodes and lungs
of 7-wk-old, PMN-MDSC-depleted and control mice. As shown in
Figure 5A, there was an 8.4-fold decrease (p=0.03) in Dct
expression in the mandibular lymph node draining the primary
tumor (left panel) and a 2.6-fold decrease (p=0.02) in Dct
expression in the lungs (central panel) of depleted mice compared
to the isotype control treated animals. A similar difference (1.8-
fold; p=0.01) was also observed in Mitf (a melanocyte-specific
transcription factor) expression in the mandibular lymph node
(Figure 5A, right panel). In addition, immunohistochemical
analysis of lung sections showed that, in 7-wk-old mice, tumor
cells present in lungs were mostly individual cells, implying that the
increased Dct expression was not due to larger micro-metastases
(Figure 5E). This finding rather shows that, in addition to
promoting peri-tumoral dissemination, PMN-MDSC favor me-
tastasis to regional and distant sites.
PMN-MDSC Favor Metastatic Outgrowth
Cancer cell dissemination to the skin of RETAAD mice cannot be
easily measured because skin contains melanocytes that express Dct
and Mitf under physiological conditions. However, we were able to
quantify the number of macroscopic cutaneous tumors in 7-wk-old
micedepleted of PMN-MDSCfrom 1wkofageandcontrolmice.As
shown in Figure 5B, there was a 40% reduction (p=0.01, Wilcoxon
matched-pairs test; two-tailed) in the number of cutaneous tumors in
mice depleted of PMN-MDSC between 1 and 7 wk of age. The
distribution of tumor sizes was similar between treated and control
animals (Figure 5C), consistent with the low percentage of PMN-
MDSC in cutaneous tumors. These data show that PMN-MDSC
infiltrating the primary tumor promote cancer cell dissemination to
cutaneous sites. This increased influx of disseminated cancer cells
results in an increased number of metastases without affecting the
average size of tumor.
Figure 3. PMN-MDSC favor tumor cell proliferation in vitro. (A) Melan-ret cells (5610
3 cells per well) were cultured with increasing
concentrations of PMN-MDSC purified from tumor-bearing RETAAD mice (12-wk-old) for 48 h. Proliferation of tumor cells was assessed by [
3H]-
thymidine incorporation. PM, PMN-MDSC only; T:PM, ratio of tumor cells to PMN-MDSC; T, tumor cells only. (B) Irradiated PMN-MDSC but not
macrophages induce Melan-ret tumor cell proliferation. Macrophages and PMN-MDSC were irradiated at 2,000 rads before co-culture with tumor cells
for 48 h. iPM, Irradiated PMN-MDSC; iMF, Irradiated macrophages; T, tumor cells. (C) PMN-MDSC-induced proliferation does not require direct contact.
PMN-MDSC and tumor cells were plated in the top and bottom wells of transwell inserts (pore size=0.4 mm; Millipore), respectively. PMN-MDSC
cultured in the upper chamber were able to induce proliferation of Melan-ret tumors cells in the bottom chamber after 48 h. Data are from four
independent experiments carried out in duplicates. Bars represent the average fold change relative to tumor cell only 6 SEM. *p value ,0.05, two-
tailed paired Student’s t test.
doi:10.1371/journal.pbio.1001162.g003
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and metastases, we previously showed that metastases derive from
cancer cells that disseminate early [5]. We therefore predicted that
if PMN-MDSC play a critical role in cancer cell dissemination,
depleting these cells after cancer cells have already colonized the
skin should have little effect on the onset of cutaneous metastases.
Indeed, delaying the onset of PMN-MDSC depletion until 5 wk of
age (Figure S3A, Scheme B) restored the incidence of cutaneous
metastases to that of control mice (Figure 5D). These data indicate
that most cutaneous tumors derive from cancer cells that
disseminate before 5 wk of age and that PMN-MDSC act at an
early stage of melanoma development.
PMN-MDSC Induce Cancer Cell EMT In Vitro
To further investigate the mechanisms by which PMN-MDSC
induce cancer cell dissemination and metastasis, we analyzed the
morphology and motility of NBT-II bladder carcinoma cells co-
cultured with PMN-MDSC purified from tumor-bearing RE-
TAAD mice. NBT-II cells were chosen as reporter cells because
they are known to undergo EMT in response to several different
stimuli [33–35]. Following co-culture with PMN-MDSC for 24 h,
NBT-II cells acquired a mesenchymal morphology (Figure 6A).
Actin microfilaments redistributed from the membrane cortex to
the basal surface, indicating loss of cell-cell contact. Moreover,
NBT-II cells exhibited numerous thin filopodia and cell surface
expression of E-Cadherin, a classical marker of epithelial cells, was
down-regulated (Figure 6A). Similar changes were observed when
NBT-II cells were treated with Hepatocyte Growth Factor (HGF),
a known inducer of EMT [36]. To assess motility, NBT-II cells
were tracked for 6 h using time-lapse video microscopy (Videos
S1–S3). As seen in Figure 6B–D, NBT-II cells co-cultured with
PMN-MDSC travelled significantly further (17469 mm versus
9565 mm, p=6.7610
212), with an increased average velocity
(53.060.9 mm/h versus 32.160.4 mm/h, p=2.8610
2106) result-
ing in a larger total displacement (80.0 6 5.5 mm versus 29.3
63.9 mm, p=3.1610
211). To assess the generality of this
observation, PMN-MDSC were co-cultured with dissociated
tumor cells from RETAAD mice. After 24 h, down-regulation of
cell surface E-Cadherin was observed in tumor cells derived from
both primary tumors (21% reduction; p=0.023) and cutaneous
metastases (22% reduction; p=0.005; Figure 6E–F). Down-
modulation of E-Cadherin gene expression was also observed in
the human melanoma cell line 888mel after co-culture with PMN-
MDSC purified from RETAAD mice (Figure 6G; 42% reduction:
p=0.025). Taken together, these data demonstrate that upon co-
culture with PMN-MDSC, cancer cells undergo morphological,
behavioral, and phenotypic changes typical of EMT.
PMN-MDSC Induce Cancer Cell EMT In Vivo
These in vitro findings led us to predict that in vivo depletion of
PMN-MDSC would affect the frequency of cancer cells undergo-
ing EMT in the primary tumor. S100A4 (also known as Fsp1) is a
small Ca
2+ binding protein involved in EMT and cell motility [37–
39]. We measured the number of S100A4
+ melanoma cells in
primary tumors. Interestingly, S100A4
+ cells were found specif-
ically in the periphery of tumor nodules (Figure 6H). Importantly
primary tumors from mice depleted of PMN-MDSC between 1
and 7 wk of age possessed a 3.6-fold lower density of S100A4
+ cells
(Figure 6I; p=3.42610
28 in two-tailed t test). Similarly, a 3.3-fold
decrease was seen in vimentin expression (Figure 6J; p=0.035 in
paired two-tailed Wilcoxon-test). Closer characterization of
S100A4
+ cells in primary tumors showed that there were indeed
delaminating melanoma cells expressing HMB45 and MART-1
antigens and exhibiting a fusiform morphology (white arrows;
Figure 6K). The number of S100A4
+ cells expressing melanoma
differentiation antigens was reduced in tumors depleted from
PMN-MDSC (Figure 6L). This observation indicates that PMN-
MDSC play a crucial role in EMT induction in melanoma cells in
vivo.
PMN-MDSC Induce EMT through Multiple Pathways
To identify the molecular pathways involved in PMN-MDSC-
induced EMT, the various cell subsets present in RETAAD
tumors were sorted by flow cytometry before performing
Figure 4. PMN-MDSC favor multinodular growth of the primary tumor. (A and B) Multinodular eye tumors from control (A) and PMN-MDSC
depleted (B) mice stained with anti-S100B antibody (depletion scheme A). (C) Number of nodules per mouse. Results are from 11 depleted (depletion
scheme A) mice (Dp) and 10 littermates injected with control antibody (Ct). *p value ,0.05, two-tailed paired t test.
doi:10.1371/journal.pbio.1001162.g004
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PLoS Biology | www.plosbiology.org 6 September 2011 | Volume 9 | Issue 9 | e1001162Figure 5. PMN-MDSC stimulate tumor cell dissemination and metastatic outgrowth. (A) Dissemination of tumor cells to the draining
mandibular lymph nodes (from 12 control and 20 depleted mice) and lungs (from 11 control and 11 depleted mice) was assessed by measuring
ectopic expression of Dct and Mitf by qRT-PCR. The graph shows the relative gene expression normalized to GAPDH in mice injected with the control
(Ct) or the anti-Ly6G antibody (Dp) (depletion scheme A). Bars represent mean 6 SEM. *p,0.05, two-tailed t test. (B) Decreased number of cutaneous
tumors in mice depleted from PMN-MDSC. Data are from 11 control and 11 PMN-MDSC-depleted mice (depletion scheme A). Bars represent mean 6
SEM. *p,0.05, two-tailed Wilcoxon matched-pairs test. (C) Depletion of PMN-MDSC does not affect the size of cutaneous tumors. The depletion
scheme A was used, but similar results were obtained with depletion scheme B (Figure S4). Bars represent mean 6 SEM. ns, non-significant. (D)
Delayed depletion of PMN-MDSC has no effect on the incidence of cutaneous metastases. Depletion scheme B was used. Data are from four control
(Ct) and six PMN-MDSC-depleted (Dp) mice. Bars represent mean 6 SEM. ns, non-significant. (E) Disseminated melanoma cells found in the lungs of 7-
wk-old mice are mostly individual cells. Red, S100B; blue, CD45.
doi:10.1371/journal.pbio.1001162.g005
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As shown in Figure 7A, PMN-MDSC were found to express
Hepatocyte Growth Factor (HGF) and Transforming Growth
Factor-b1 (TGF-b1), while cancer cells were the main source of
Epidermal Growth Factor (EGF). To determine whether these
factors played any role in PMN-MDSC-induced EMT, NBT-II
cells were pre-treated with various inhibitors before co-culture with
PMN-MDSC. After 24 h, NBT-II cells were stained with
desmoplakin to visualize the desmosomes that are typically found
at the junctions between epithelial cells (Figure 7B). Addition of
PMN-MDSC to untreated NBT-II cells resulted in the complete
dissociation of the desmosomal complexes at the cell surface and
their translocation into the cytoplasm. Cell scattering was strongly
reduced by pre-treatment of NBT-II cells with SB525334, a specific
inhibitor of the receptor for TGF receptor 1 (TGF-bR1).
Nevertheless, most desmoplakin junctions were lost. In contrast,
most cells treated with JNJ38877605, a specific inhibitor of the
receptor for HGF (HGFR), retain desmoplakin at cell-cell junctions.
Further inhibition of EMT was observed when NBT-II cells were
pretreated with SB525334 together with JNJ38877605 and/or
PD153035, a specific inhibitor of the receptor for EGF (EGFR).
Pre-treatment of NBT-II cells with all three inhibitors completely
reversed the effect of PMN-MDSC. Similar results were obtained
when a different set of inhibitors was used (Figure S7). Taken
together, these results demonstrate that TGF-b1, EGF, and HGF
play a crucial role in EMT induction by PMN-MDSC.
Discussion
Recent data suggest that primary tumor cells acquire a metastatic
phenotype during the early stages of cancer progression [5,40]. This
hypothesis led to a conundrum, as the previously accepted theory of
random accumulation of mutations leading to the metastatic
phenotype was unable to explain such rapid cancer cell dissemina-
tion. Here we show that a particular subset of immune cells
preferentially infiltrates primary tumors, induces EMT in primary
tumor cells, and promotes cancer cell dissemination. Therefore, in
our mouse model of melanoma, acquisition of a motile phenotype
by cancer cells is instructed by tumor-infiltrating MDSC and occurs
early in the development of the primary tumor.
MDSC accumulate in the tumors, spleen, and blood of tumor-
bearing mice [19,41]. In the RETAAD model, we uncovered a
preferential recruitment of PMN-MDSC to primary tumors
compared to cutaneous metastases, which correlated with a more
inflammatory microenvironment. Importantly the chemokines
CCL19, CXCL1, CXCL2, and CXCL5 were significantly more
highly expressed in primary tumors. CXCL1, CXCL2, and
CXCL5 are known chemoattractants for neutrophils [42,43] and,
as shown here for the first time to our knowledge, potent
attractants of PMN-MDSC as well. CXCR2, the receptor for
CXCL2, CXCL5, and CXCL1, is specifically expressed on PMN-
MDSC purified from RETAAD tumors (Figure S2). Pharmaceu-
tical inhibition of CXCR2 reduced PMN-MDSC attraction by
melanoma cells in vitro and genetic deletion of CXCR2 impaired
their recruitment to the primary tumor in vivo. Since CXCL5 is
the most highly expressed of the three CXCR2 ligands, it is the
prime candidate for mediating the preferential attraction of PMN-
MDSC to the tumor. In addition, since CXCL1 and CXCL2 are
expressed by PMN-MDSC purified from RETAAD tumors, we
propose that these two chemokines provide a positive feedback
loop that further amplifies the accumulation of PMN-MDSC in
primary tumors. Of note, CXCL1 and IL-8, the human ortholog
of CXCL5, are expressed by human melanoma cells [44,45].
Depletion of PMN-MDSC from 1 wk of age resulted in a
decreased density of proliferating cells in primary tumors.
Although no significant effect on tumor size was detected at 7
wk, when depletion was performed from 5 wk until 20 wk of age,
primary tumors were much smaller. Importantly the size of
cutaneous metastases, which contain few PMN-MDSC, was not
affected by the depletion. Three sets of observations suggest that
this effect is due to a direct action of PMN-MDSC on cancer cells.
Firstly, highly purified PMN-MDSC stimulated the proliferation of
Melan-Ret cells in vitro. This effect was mediated by soluble
factors secreted by PMN-MDSC, since it did not require direct
contact with the melanoma cells. Secondly, PMN-MDSC were the
only tumor-infiltrating cells whose number was reduced by the
antibody treatment; monocytes (CD11b
+Gr1
loF4/80
lo) were
unaffected and macrophage (CD11b
+Gr1
2F4/80
+) density was,
if anything, slightly increased. Finally the number of endothelial
cells (CD45
2CD31
+) was slightly increased in PMN-MDSC
depleted tumors, showing that PMN-MDSC stimulated tumor
growth independently of angiogenesis.
EMT has been suggested to be an essential step in cancer cell
dissemination and metastasis [36]. Artificial induction of EMT in
cancer cell lines promotes metastatic potential [46]. The aggressive
Figure 6. PMN-MDSC induce EMT in vitro and in vivo. (A) PMN-MDSC (1610
4 cells per well) were purified from 12-wk-old RETAAD mice and
co-cultured with NBT-II cells for 24 h. HGF (5 ng/ml) was added as a positive control for induction of EMT. Green, Actin (upper panel) or E-Cadherin
(lower panel); red, H2b (nuclear stain). Images are representative of three independent experiments. (B–D) Individual colonies of NBT-II cells were
tracked for 6 h (during hours 12–18) out of the 22 h captured. Tracks of 59 cells from the control and 32 cells co-cultured with PMN-MDSC (1610
4
cells per well) were analyzed. Panel B illustrates the individual tracks of all the cells in the colony. Panels C and D show an increase in distance
traveled, speed, and displacement of NBT-II cells when co-cultured with PMN-MDSC. PM, PMN-MDSC; Ct, Control. Bars represent mean 6 SEM.
***p,0.0001, two-tailed t test. (E) Primary RETAAD tumors (top panel) or cutaneous metastases (bottom panel) were dissociated and co-cultured for
24 h with (black line) or without (red line) PMN-MDSC purified from the same mouse. Data are gated on CD45
2 live cells. Filled histograms: isotype
control. (F) Co-culture for 24 h with PMN-MDSC (as described in Figure 6E) induced a decrease in the number of tumor cells expressing E-Cadherin.
Data are from five primary tumors and five cutaneous metastases in three independent experiments. Bars represent the mean decrease in the
number of live CD45
2 E-Cadherin
+ cells 6 SEM *p,0.05, **p,0.01, two-tailed t test. (G) PMN-MDSC decrease CDH1 gene expression in vitro. Human
melanoma cell line, 888mel, was co-cultured with PMN-MDSC purified from a tumor-bearing RETAAD mouse. Cells were washed and harvested after
24 h. Data are from three independent experiments. Bars represent mean 6 SEM *p,0.05. (H–I) Staining for S100A4 in primary eye tumor nodules.
Panel H is a representative staining of primary tumors for S100A4. Red, S100A4; blue, Heamatoxylin (Nuclear stain). Panel I shows a decrease in the
percentage of S100A4
+ cells in the tumors depleted from PMN-MDSC (depletion scheme A). Dp, PMN-MDSC depleted mice; Ct, Control mice. Bars
represent mean 6 SEM of 176 control and 87 PMN-MDSC depleted tumor nodules. ***p,0.0001, two-tailed t test. (J) Decreased percentage of
vimentin
+ cells in tumors depleted from PMN-MDSC (depletion scheme A). Dp, PMN-MDSC depleted mice; Ct, Control mice. Bars represent mean 6
SEM of 14 pairs of primary tumors. *p,0.05, two-tailed paired t test. (K) The majority of S100A4
+ cells express melanoma specific antigens. Eye tumors
were co-stained for melanoma antigens (HMB45 and MelanA/MART-1) and S100A4. White arrows indicate S100A4
+ melanoma cells exhibiting a
fusiform morphology. Note the different morphologies of the double-stained mesenchymal-like cells and single-stained ones. Blue, DAPI (nucleus);
green, HMB45/DT101/BC199 (melanoma); red, S100A4. (L) Decreased percentage of S100A4+ melanoma cells in tumors depleted from PMN-MDSC
(depletion scheme A). Double positive cells stained for HMB45/MART-1 and S100A4 were quantified from three depleted (Dp) and three control (Ct)
mice.
doi:10.1371/journal.pbio.1001162.g006
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PLoS Biology | www.plosbiology.org 10 September 2011 | Volume 9 | Issue 9 | e1001162behavior of melanoma has been attributed to its propensity to
undergo EMT [47]. In the present study we show that purified
PMN-MDSC induce typical features of EMT in vitro in
melanoma and bladder human cell lines and in cells freshly
isolated from primary and metastatic RETAAD tumors. In vivo,
depletion of PMN-MDSC reduced the density of vimentin and
S100A4 expressing cells in the primary tumor. Vimentin is a
classical mesenchymal marker, while S100A4, a target of the EMT
inducer Snail [48], is known to down-regulate E-Cadherin in
mammary epithelial cell lines [49]. Collectively these observations
indicate that PMN-MDSC play a crucial role in cancer cell EMT
in vivo. Interestingly, expression of S100A4 correlates with shorter
patient survival in several cancers, including melanoma [50].
PMN-MDSC-induced EMT results in multinodular develop-
ment of the primary tumor, since mice depleted of PMN-MDSC
had primary tumors composed of fewer nodules. This observation
is in agreement with previous findings that multinodular growth
requires cell motility [30,31]. At 7 wk, decreased nodularity in
PMN-MDSC-depleted tumors was observed in the absence of
reduction in the whole tumor size, consistent with spatial
redistribution of cancer cells, rather than inhibition of their
development. In contrast, cutaneous tumors typically do not
display such a multinodular structure, which is consistent with
their low content of PMN-MDSC. In humans, many primary
tumors exhibit higher fractal dimensions than normal tissue, as a
result of their multinodular morphology. This morphology is
thought to facilitate exponential growth of small avascular tumors,
since in silico modeling indicates that the optimal tumor
morphology under strong nutrient limitation is fractal [31,51].
Therefore, induction of EMT in cancer cells is likely to be selected
because it favors the growth of the primary tumor.
PMN-MDSC-induced EMT was also associated with cancer
cell dissemination and metastatic outgrowth. Cancer cell dissem-
ination was assessed in the regional lymph nodes and in the lungs
by measuring Dct and Mitf expression. As shown previously, Dct
expression correlates with the presence of S100B
+ melanoma cells
detected by IHC [5]. PMN-MDSC depletion from 1 wk of age
resulted in reduced dissemination by as early as 7 wk. Reduced
primary tumor burden could not explain the decreased cancer cell
dissemination, since decreased expression of melanoma markers in
the mandibular LN and the lungs preceded the effect on primary
tumor size: no change in primary tumor size could be detected at 7
wk. Decreased Dct and Mitf expression after PMN-MDSC
depletion could result from decreased influx of and/or decreased
proliferation of cancer cells in the lungs. The latter might be
expected because PMN-MDSC favor cancer cell proliferation and
suppress CD8
+ T cell activity. We cannot exclude any of these
explanations. In fact RETAAD mice possess increased numbers of
PMN-MDSC in their lungs when compared with non-transgenic
littermates (unpublished data). Furthermore CD8
+ T cells control
the proliferation of disseminated cancer cells in the lungs [5].
However, in our experiments, Dct expression was measured at an
early time point (7 wk of age) and lung micrometastases have a low
mitotic index in untreated animals (1.9% + 0.5%; [5]). We
calculated that even an 80% inhibition of cancer cell proliferation
in the lungs could not account for the observed decrease in Dct
expression (Text S1). Moreover, immunohistochemistry analysis of
lungs from control and depleted mice at 7 wk revealed mostly
individual cancer cells (CD45
-S100B
+) (Figure 5E). We therefore
favor the interpretation that the decrease observed in Dct
expression is mainly due to reduced colonization of the lungs by
cancer cells rather than reduced proliferation.
Analysis of cutaneous metastases provided further support for
decreased cancer cell dissemination in mice depleted of PMN-
MDSC. Since PMN-MDSC poorly infiltrate cutaneous tumors,
depletion was less likely to affect cancer cell proliferation in this
site. If PMN-MDSC were acting by promoting metastatic growth
rather than dissemination, we would expect to see smaller
metastases in depleted mice. However, depletion of PMN-MDSC
from 1 wk of age reduces the number of cutaneous tumors
(Figure 5B), but not their size (Figure 5C). Interestingly, when
PMN-MDSC depletion was started at 5 wk of age (i.e. 2–3 wk after
the initiation of cancer cell dissemination), no significant change
was seen in the number of cutaneous metastases (Figure 5D). This
shows that metastatic potential had already been acquired at 5 wk
and that cancer cells disseminating before 5 wk contain tumor
initiating cells.
Depletion of PMN-MDSC resulted in a very significant
inhibition of tumor cell dissemination (85% reduction in the
draining lymph node, 74% in the lung, 40% reduction in the
incidence of cutaneous tumors) and EMT (68% reduction in
S100A4
+ cells and 70% reduction in vimentin
+ cells). Other tumor
infiltrating immune cells have been shown to favor metastasis. In a
mammary tumor model, CD11b
+Gr1
+ cells were shown to
accumulate in the primary tumor and promote metastasis through
increased production of MMP. Interestingly, in this model, EMT
was not involved [52]. In a model of colorectal cancer,
accumulation of immature myeloid cells distinct from MDSC
favored invasion through the production of MMP [53]. PMN-
MDSC from RETAAD tumors also produce MMP, mostly
MMP9, but when RETAAD mice were crossed to an MMP9-
KO background, no significant difference was observed in cancer
cell dissemination or in the incidence of cutaneous metastases
(unpublished data). Therefore, myeloid cells that infiltrate the
primary tumor could contribute to metastasis through more than
one mechanism.
Transcriptome analysis of the various cell subsets purified from
RETAAD tumors showed that PMN-MDSC express TGF-b1 and
HGF, whereas melanoma cells express EGF (Figure 7). This
observation extends previous studies in a mammary tumor model
showing that MDSC represent an abundant source of intratu-
moral TGF-b [52,54]. We found that specific inhibitors of the
corresponding receptors blocked PMN-MDSC mediated induc-
tion of EMT. The fact that EGF inhibitors reduced EMT
induction while PMN-MDSC purified from RETAAD tumors did
not produce EGF may suggest that PMN-MDSC stimulate EGF
production by the cancer cells.
Cancer progression has been often depicted as a linear process,
during which the incipient cancer cell sequentially accumulates
genetic and epigenetic changes that confer the hallmarks of cancer
cells [55]. Here we show that some of these properties can be
induced by cues provided by the immune stroma of the primary
Figure 7. Inducers of EMT. (A) Expression of Hgf, Egf, and Tgfb1 genes in RETAAD tumors analyzed by qRT-PCR. Hgf and Tgfb1 are preferentially
expressed in PMN-MDSC, while Egf is preferentially expressed in tumor cells. Data are from four individual experiments using sorted fractions of PMN-
MDSC and melanoma cells. Bars represent mean 6 SD. (B) NBT-II cells (100 cells per well) were plated for 4 d to allow for colony growth and were pre-
treated for 24 h with inhibitors before the addition of PMN-MDSC. After co-culture with PMN-MDSCs in the presence of inhibitors, cells were fixed
and stained with anti-rat desmoplakin. Green, Desmoplakin; red, H2b (nuclear stain). PD153035 – EGFR inhibitor, JNJ38877605 – c-met (HGFR)
inhibitor, and SB525334 – TGF-bR1 inhibitor. Images are representative of three independent experiments.
doi:10.1371/journal.pbio.1001162.g007
Tumor Cell Dissemination Is Driven by MDSC
PLoS Biology | www.plosbiology.org 11 September 2011 | Volume 9 | Issue 9 | e1001162tumor. Once the cell migrates out of the primary tumor, it may
well lapse back to its original phenotype and, for example, undergo
mesenchymal-epithelial transformation. Such a transient pheno-
typic switch may accelerate carcinogenesis and participate in the
plasticity of cancer cells [56,57].
Tumor infiltration by myeloid cells is associated with a poor
prognosis for cancer patients. Most studies have focused on the
role of macrophages [10,58–61], whereas MDSC have been
primarily characterized for their effects on immune cells [18,62–
66], stromal cells [67], or endothelial cells [68]. The present study
demonstrates for the first time that PMN-MDSC act on cancer
cells to promote proliferation, EMT, and dissemination. In turn, it
provides a mechanistic explanation for the long-recognized link
between inflammation and cancer progression.
Materials and Methods
Mice
Animal care and experimental procedures were approved by
the IACUC (Application No. 090425) of the Biological Resource
Center, 20 Biopolis Way, Singapore 138668. The generation of
RETAAD mice has been previously described [69]. Rosa mT/mG
reporter mice expressing tdTomato and Il8rb-KO mice were
obtained for JAX Laboratories (Cat No. 007576 and 006848,
respectively). Il8rb-KO mice were crossed with mice expressing
EGFP under the Lysozyme promoter [70] to obtain Gr1
hi cells
lacking CXCR2 and expressing EGFP.
Antibodies
Anti-CD45-FITC, anti-CD19-PE, anti-CD11c-PerCP/Cy5.5,
anti-Gr1-PE/Cy7, anti-F4/80-APC, anti-CD11b-APC/Cy7, anti-
CD3-PE, anti-CD4-PerCP/Cy5.5,anti-CD8-PE/Cy7, anti-NK1.1-
APC, and anti-CD45-PE antibodies were from Biolegend, and anti-
I-A/I-E-eFluor450 and anti-CD45-eFluor450 antibodies were from
eBioscience. Anti-Melanoma antibody (ab732) was obtained from
Abcam. Anti-rat E-Cadherin antibody was from BD Pharmingen
while anti-mouse E-cadherin antibody was from R&D Systems.
Anti-mouse vimentin antibody was from Proteintech Group.
Flow Cytometry
Tumors were dissected from RETAAD mice and single cell
suspensions were obtained by digestion with Collagenase A (1 mg/
ml; Roche) and DNase I (0.1 mg/ml, Roche) for 20 min at 37uC
followed by filtration through a 70 mm filter (BD Biosciences).
Flow cytometric data were acquired on the BD LSRII (BD
Bioscience) and analyzed using FlowJo software (Tree Star, Inc.).
Migration Assay
Dissociated tumor cells or recombinant CXCL1, CXCL2, and
CXCL5 (R&D Systems) were placed in the bottom chamber of a
24-well plate, and 1610
6 total cells from the blood and spleen of
12-wk-old RETAAD mice were placed in the upper chamber
(3 mm, BD Falcon). Cells were allowed to migrate to the bottom
well for 3 h at 37uC, 5% CO2. Migrated cells were then analyzed
by flow cytometry on the BD FACSCalibur and quantified using
CountBright Absolute Counting Beads (Invitrogen). For the
inhibition of CXCR2, PMN-MDSC were treated 1 h before
and during the migration assay with inhibitors SB225002 and
SB265610 from Tocris Bioscience.
For the in vivo migration assay, 5610
6 bone marrow cells from
Rosa mT/mG reporter mice expressing tdTomato and an equal
number of Il8r-KO bone marrow cells expressing GFP were
injected intra-orbitally into tumor-bearing RETAAD mice. After
18 h, the ratio of tdTomato
+ cells to GFP
+ Gr1
hi cells infiltrating
the contra-lateral tumor was measured by flow cytometry.
qRT-PCR
For each mouse (n=11), RNA was extracted from one primary
tumor and one cutaneous tumor and gene expression was
analyzed using Mouse Common Cytokines PCR Arrays (SABios-
ciences, PAMM-021) and Mouse Inflammatory Cytokines &
Receptors PCR Arrays (SABiosciences, PAMM-011) following the
manufacturer’s instructions. CXCL2 was analyzed separately
using the following primers: 5’-AGTGAACTGCGCTGT-
CAATG-3’ and 5’-GAGAGTGGCTATGACTTCTGTCTG-3’.
Gene expression was normalized to GAPDH expression, and p
values were calculated using a two-tailed paired t test. Dct
expression was measured as previously described [5].
In Vivo PMN-MDSC Depletion
Mice were injected intraperitoneally twice a week with 0.25 mg
of anti-Ly6G NIMP-R14 antibody [71] or control rat IgG (Sigma-
Aldrich). Efficiency of PMN-MDSC depletion was monitored by
flow cytometry. Mice were clinically assessed for palpable tumors
once per fortnight. Injection schedules are as illustrated in Figure
S3A.
Immunohistochemistry
Formalin-fixed paraffin-embedded sections (5 mm) were immu-
nolabeled for S100B and Ki67 as described previously [5] or for
S100A4 (Abcam; ab27957). Tumor areas were assessed using
ImagePro Analyzer 6.2 software (Media Cybernetics Inc.). Total
cell number was calculated by dividing the tumor area by the
average area of one cancer cell (estimated to be 82 mm
2). The
mitotic index was calculated as follows:
Mitotic index~
No: of Ki67 positive cells
Total number of cells
|100
Isolation of PMN-MDSC and Macrophages
PMN-MDSC and macrophages were isolated using an
immune-magnetic separation kit—EasySep Mouse PE Positive
Selection Kit (STEMCELL Technologies)—according to the
manufacturer’s protocol. Briefly, PMN-MDSC and macrophages
from the blood and spleen of 12-wk-old mice were labeled with
anti-Ly6G-PE (1A8; BD Bioscience) or anti-F4/80-PE (BM8;
eBioscience) antibodies, respectively. PE-labeled cells were im-
muno-magnetically labeled and positively selected using an
EasySep magnet. Cell purity was verified by flow cytometry and
was always .80%.
OVA-Specific T Cell Proliferation Assay
CD8
+ T cells were isolated from the spleen of C.Cg-Rag2
tm1Fwa
Tg(DO11.10)10Dlo (Taconic #4219) using a CD8a
+ TC e l l
Isolation Kit (Miltenyi Biotec). 1610
5 isolated T cells were plated
with 2610
4 irradiated (2,000 rads) cells from the CD8
- fraction.
PMN-MDSC isolated from tumor-bearing mice (12-wk-old) were
added at a ratio of 1:1, 1:4, 1:16, and 1:64 to T cells. 5 mg/ml of
SIINFEKLpeptide(GLBiochem)wasadded.After96 hincubation,
T cell proliferation was measured by [
3H]thymidine incorporation.
EMT Assay
NBT-II cells, expressing histone H2B-mCherry, were seeded at
a density of 100 cells per well on Ibidi 8 well m-slides and left in
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MDSC (1610
4 cells/ml) were added on day 4 and left in co-
culture for 24 h. EGF (100 ng/ml; Sigma) was used as a positive
control. Inhibitors used were TGF-b1 receptor inhibitor, SB
525334 (Tocris; final concentration 10 mM), EGF receptor
inhibitor, PD 153035 hydrochloride (Tocris; final concentration
8 mM), and HGF receptor inhibitor, JNJ38877605 (Selleck
Chemicals; final concentration 5 mM). Time-lapse images were
captured with an Olympus FV-1000 confocal system and
analyzed with MacBiophotonics ImageJ [72] and Imaris (Bit-
plane). NBT-II cells were then fixed and stained with Phalloidin-
Alexa Fluor 488 (Invitrogen) and mouse anti-rat Desmoplakin
(Millipore; clone DP2.15). A goat anti-mouse antibody conjugat-
ed to Alexa Fluor 488 (Invitrogen) was used as a secondary
antibody. Fluorescent images were captured with an Olympus
IX-81 Inverted microscope and Retiva-SRV CCD Camera
(QImaging) and analyzed with ImagePro analysis software
(MediaCybernetics).
Statistics
Gene expression data were log-transformed before analysis
using Student’s t test. Statistical tests used to analyze other data are
described in the individual figure legends. Prism (GraphPad Inc.)
and Excel (Microsoft) softwares were used for calculations and
graphing. p values less than 0.05 were considered statistically
significant.
Supporting Information
Figure S1 Accumulation of PMN-MDSC during melanoma
progression and gating strategy. (A and B) PMN-MDSC were
quantified by flow cytometry in the (A) spleen and (B) blood of
RETAAD mice (RET
+) and non-transgenic littermates (ret
2).
RETAAD mice displayed no sign of disease (Nil), exophthalmos
(Ex), or macroscopic tumors (Tum). Graphs show the frequencies
of CD11b
+Gr1
hi cells among CD45
+ cells. Bars represent mean 6
SEM of four mice per group.*p value ,0.05, **p value ,0.01. (C)
CD11b
+Gr1
hi cells isolated from the spleen and blood of tumor-
bearing mice (12-wk-old) inhibit T cell proliferation in a dose-
dependent manner. Bars represent mean 6 SEM; assay was
performed in triplicate. (D) The figure shows the strategy used to
enumerate myeloid cells in Figure 1: plasmacytoid dendritic cells
(pDC), CD103
+ and CD11b
+ DC, PMN-MDSC, Mo-MDSC, and
Macrophages. The bottom right panel shows May-Gru ¨nwald
Giemsa staining of PMN-MDSC.
(TIF)
Figure S2 Expression of CXCR2 and its ligands in RETAAD
tumors. CXCR2 (Il8rb), CXCL1, and CXCL2 are preferentially
expressed in tumor-infiltrating PMN-MDSC, while CXCL5 is
preferentially expressed by tumor cells. Data are from four
individual experiments from sorted fractions of PMN-MDSCs and
tumor cells. Bars represent mean 6 SD.
(TIF)
Figure S3 Depletion of PMN-MDSC in RETAAD mice. (A)
Schematic diagram illustrating the two depletion protocols used in
this study. (B) Quantification of PMN-MDSC, Monocytic
myeloid-derived suppressor cells (Mo-MDSC), and Macrophages
in five individual tumors from mice injected with NIMP-R14 (Dp)
and three individual tumors from mice injected with control (Ct)
antibody (depletion scheme B). Bars represent mean 6 SEM.
*p value ,0.05; ns, non-significant.
(TIF)
Figure S4 Depletion of PMN-MDSC does not affect the size of
cutaneous metastases. Data are from 20-wk-old mice injected with
control antibody (n=6) or with anti-Ly6G antibody (n=4) for 15
wk (depletion scheme B). Ns, non-significant, two-tailed t test.
(TIF)
Figure S5 PMN-MDSC depletion does not reduce vascularisa-
tion of the primary tumor. (A) Representative images of tumor
vasculature (black arrows) in 7-wk-old-mice. No significant
difference could be observed between the control and PMN-
MDSC depleted samples. Depletion scheme A. (B) Quantification
of endothelial cells (CD45
2CD31
+) by flow cytometry in five
individual tumors from mice injected with NIMP-R14 (Dp) and
three individual tumors from mice injected with control (Ct)
antibody. Depletion scheme B. Bars represent mean 6 SEM. Ns,
non-significant.
(TIF)
Figure S6 Depletion of PMN-MDSC has no effect on the size of
the primary tumor at 7 wk. Data are from 18 control and 22
PMN-MDSC depleted primary tumors (Depletion scheme A).
Bars represent mean 6 SEM. ns, non-significant.
(TIF)
Figure S7 Alternative Inhibitors block PMN-MDSC induced
EMT. Alternative inhibitors block PMN-MDSC induced EMT in
NBT-II cells. AG1478– EGFR inhibitor, SGX523– c-met
(HGFR) inhibitor, and SB431542– TGF-bR1 inhibitor.
(TIF)
Table S1 Differential expression of chemokines and cytokines in
primary tumors and metastases. Gene expression was measured by
low density qRT-PCR arrays (except for CXCL2 which was done
by individual qRT-PCR). Expression values were normalized to
GAPDH and presented as log2(expression in primary tumor/
metastases). p values were calculated using two-tailed paired t test.
Data are from 11 paired primary tumors and metastases. Each
pair of primary and metastatic tumors is taken from the same
individual mouse.
(DOC)
Text S1 Calculations used to estimate tumor size and Dct
expression levels. Calculations were made to estimate the
theoretical tumor size at 7 wk and 20 wk of age. Calculations
were also made to estimate the theoretical decrease in Dct
expression if cancer cell proliferation was inhibited by 80% in the
lungs.
(DOC)
Video S1 Induction of EMT by PMN-MDSC. Videos of time
lapse DIC images over 22 h displaying NBT-II cells without
stimulation
(MOV)
Video S2 Induction of EMT by PMN-MDSC. Videos of time
lapse DIC images over 22 h displaying NBT-II cells with EGF
(100 ng/ml).
(MOV)
Video S3 Induction of EMT by PMN-MDSC. Videos of time
lapse DIC images over 22 h displaying NBT-II cells with PMN-
MDSC (1610
4 cells/well).
(MOV)
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